Dermatologists

Three parts of your work where AI is already doing real lifting, and what stays yours.

• Clinical morphology1836–1893

  Clinical morphology and bedside diagnosis (Willan classification era)

  The dermatologist's core tool from Bulkley's 1836 dispensary through the end of the 19th century was the trained eye. Robert Willan's 1808 morphological classification system -- describing skin conditions by their primary lesion type (macule, papule, vesicle, pustule, wheal, bulla) -- gave the specialty its diagnostic vocabulary. A dermatologist of this era carried a hand lens and relied on inspection under natural light, knowledge of disease patterns, and patient history to distinguish syphilitic eruptions, infectious dermatoses, and inflammatory conditions in a world without germ theory, patch testing, or biopsy. The Broome Street Infirmary and its successors collected patients in sufficient volume to make pattern recognition possible across hundreds of cases, a practice model that would later be called clinicopathological correlation.

• Dermatoscope / diascope1893–1940

  Dermatoscope / diascope and skin histopathology (Unna 1893; Wood's lamp 1903)

  Paul Gerson Unna of Hamburg published his technique of "diaskopie" in 1893, using immersion oil with a glass lens to render the uppermost epidermal layers translucent and reveal the vascular and structural features of skin lesions below. This was the conceptual ancestor of the modern dermatoscope. In the same era, Unna's 1894 landmark text on cutaneous histopathology established a rigorous laboratory science for the specialty, and Robert Wood's ultraviolet lamp (introduced to dermatology around 1903) allowed fluorescence-based identification of fungal and bacterial skin infections. The Wood's lamp remained a workhorse diagnostic tool for tinea capitis and pityriasis versicolor well into the late 20th century. These tools moved dermatology from pure clinical observation into laboratory-augmented diagnosis, a transition that accelerated with the spread of hospital-based skin clinics in the early 20th century.

• Mohs micrographic surgery1940–1974

  Mohs micrographic surgery and broadband UV phototherapy (Frederic Mohs 1936-1940; Goeckerman UVB 1923; widespread procedural dermatology)

  Frederic Mohs treated his first patient with microscopically controlled excision on June 30, 1936, and by 1940 had refined the technique into a systematic procedure using a zinc chloride paste to fix tissue in situ before staged removal. Mohs surgery transformed what dermatologists could offer patients with skin cancer on cosmetically sensitive sites: the nose, ears, eyelids, and lips where the margin-controlled approach dramatically improved cure rates while minimizing tissue sacrifice. Early Mohs was performed under local anesthesia in an outpatient office setting, foreshadowing the shift of procedural dermatology away from hospital operating rooms. Simultaneously, William Henry Goeckerman's 1923 protocol combining coal tar with broadband UVB became the standard treatment for severe psoriasis and anchored phototherapy as a procedural tool. These developments made dermatology increasingly procedure-heavy, a structural feature that would later resist AI displacement.

• PUVA photochemotherapy1974–1995

  PUVA photochemotherapy, first lasers, and board certification standards (1974-1995)

  In 1974, John Parrish at Massachusetts General Hospital successfully introduced psoralen plus UVA (PUVA) photochemotherapy, combining 8-methoxypsoralen with a newly developed high-intensity UVA light source. PUVA proved highly effective for psoriasis, vitiligo, and cutaneous T-cell lymphoma, transforming dermatology offices into phototherapy centers with dedicated light boxes and specialized scheduling. In 1963, Leon Goldman had pioneered the pulsed ruby laser for selective destruction of pigmented lesions; by the 1970s-1980s argon and CO2 lasers were entering dermatology practice for port-wine stains, tattoo removal, and resurfacing. The American Board of Dermatology, which had administered its first exams in 1933, now required a three-year residency for board eligibility (enacted 1938), creating a standardized pipeline whose graduates were certified proceduralists as well as diagnosticians.

• Digital dermoscopy1995–2010

  Digital dermoscopy, biological therapies, and cosmetic dermatology boom (botulinum toxin FDA 2002; biologics 2002-2008)

  The late 1990s and early 2000s transformed dermatology across three dimensions simultaneously. First, digital dermoscopy moved from research curiosity to clinical tool: videodermatoscopes allowed the capture, storage, and serial comparison of dermoscopic images, turning the visual subspecialty into a data-generating practice. Second, the biological therapy era arrived: etanercept received FDA approval for psoriatic arthritis in 2002 and psoriasis in 2004; adalimumab for psoriasis in 2008, ushering in a new practice model of managing patients on complex immunomodulatory agents with monthly monitoring and lab review. Third, the FDA approved botulinum toxin (Botox) for cosmetic use in April 2002, and hyaluronic acid fillers followed in 2003. The cosmetic dermatology market exploded: procedures that had required a plastic surgeon now belonged to a dermatologist's afternoon schedule, transforming the compensation structure of the specialty and making dermatology among the most lucrative residency matches in American medicine.

  Effect on the work

  The cosmetic dermatology boom drove compensation growth: median dermatologist starting salaries reached $420,000 by 2019, placing the specialty in the top six for starting compensation across all of US medicine.

• Teledermatology2010–2020

  Teledermatology, whole-slide digital pathology, and EHR integration (store-and-forward 2010s; digital pathology 2007+)

  Teledermatology -- pioneered during US military operations in Somalia in 1992 but mainstreamed in civilian practice only in the 2010s -- allowed dermatologists to review patient-submitted or clinician-captured photographs asynchronously (store-and-forward) without a real-time visit. Whole-slide imaging, commercially available since the late 1990s, began moving toward mainstream dermatopathology adoption after 2007, when digital pathology crossed an inflection point in processing speed and storage economics. The broader EHR adoption wave (accelerated by the HITECH Act of 2009) also reshaped dermatology documentation: practice management moved onto integrated platforms that combined scheduling, billing, and clinical notes, setting the stage for the ambient AI documentation tools that followed.

• AI dermoscopy2020–present

  AI dermoscopy, ambient documentation AI, and FDA-cleared skin cancer detection devices (DermaSensor 2024; Dragon Copilot; 15+ approved AI tools globally)

  The 2020s brought the largest technology inflection in dermatology since the cosmetic boom of the early 2000s, this time driven by AI. Dragon Copilot (rebranded from Nuance DAX Copilot in March 2025) achieved a 22% reduction in daily EHR time in a dermatology-specific pilot study, cutting per-encounter documentation. DermaSensor received FDA clearance on January 17, 2024 as the first AI-powered medical device authorized to detect all three common skin cancers, achieving 96.5% sensitivity across melanoma, basal cell carcinoma, and squamous cell carcinoma. The AAD reported several regulatory-approved AI devices in dermatology globally by 2025, with the NICE Early Value Assessment recommending Skin Analytics DERM for NHS use in May 2025, citing its ability to halve referrals on the urgent skin cancer pathway while maintaining safety. Within the practice, AI prior authorization tools began automating a burden that consumed several hours per week per dermatologist (Adonis.io 2025). These tools augment rather than threaten the licensed procedural core: Mohs surgery, biopsies, cosmetic injectables, and laser procedures remain entirely hands-on.

  Effect on the work

  AI tools are expanding effective dermatologist capacity rather than reducing the headcount.